Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Assets: 2019-2024

Historic Assets for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $1.1 billion.

  • Beam Therapeutics' Assets rose 11.93% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 11.93%. This contributed to the annual value of $1.1 billion for FY2024, which is 24.38% down from last year.
  • As of FY2024, Beam Therapeutics' Assets stood at $1.1 billion, which was down 24.38% from $1.5 billion recorded in FY2023.
  • Over the past 5 years, Beam Therapeutics' Assets peaked at $1.5 billion during FY2021, and registered a low of $451.7 million during FY2020.
  • In the last 3 years, Beam Therapeutics' Assets had a median value of $1.3 billion in 2022 and averaged $1.3 billion.
  • Its Assets has fluctuated over the past 5 years, first skyrocketed by 226.44% in 2021, then declined by 24.38% in 2024.
  • Yearly analysis of 5 years shows Beam Therapeutics' Assets stood at $451.7 million in 2020, then spiked by 226.44% to $1.5 billion in 2021, then fell by 9.00% to $1.3 billion in 2022, then grew by 8.79% to $1.5 billion in 2023, then decreased by 24.38% to $1.1 billion in 2024.